No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
www.concordbiotech.comNo one on the platform currently holds CONCORDBIO.NS.
No tracked institution reports a position in CONCORDBIO.NS as of their last filing.
No one on the platform has traded CONCORDBIO.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.0% | 23.4% | — | — | — | |
| Rev. Growth % | -12.1% | 11.3% | ||||
| Profit Margin % | 24.7% | 27.7% | ||||
| Free Cash Flow Margin % | 16.5% | 12.9% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $12.9B | +11.8% | $32.65 | $30.79–$33.79 | — | 4 |
| 2028 | $15.7B | +21.5% | $42.54 | $38.80–$48.00 | — | 4 |
| 2029 | $18.7B | +19.0% | $52.90 | $50.16–$57.56 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $7.38 | $5.63 | -23.7% |
| 2026-05-29 | $8.90 | $8.50 | -4.5% |
| 2026-02-11 | $7.20 | $6.30 | -12.5% |
| 2025-11-13 | $5.30 | $6.03 | +13.8% |
| 2025-08-08 | $6.15 | $4.20 | -31.7% |
| 2025-05-29 | $10.04 | $13.39 | +33.4% |
| 2025-02-13 | $8.90 | $7.30 | -18.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| CONCORDBIO.NSConcord Biotech Limited | $1450.80 | -1.51% | $151.8B | — |
| BLUEJET.BOBlue Jet Healthcare Limited | $557.60 | +1.23% | $96.4B | — |
| BLUEJET.NSBlue Jet Healthcare Limited | $568.00 | +3.15% | $98.5B | — |
| CAPLIPOINT.NSCaplin Point Laboratories Limited | $2566.90 | -0.14% | $195.1B | — |
| GRANULES.BOGranules India Limited |
| $854.75 |
| -2.03% |
| $212.8B |
| — |
| GRANULES.NSGranules India Limited | $857.25 | -1.76% | $212.4B | — |
| JUBLINGREA.NSJubilant Ingrevia Limited | $632.45 | +0.31% | $99.7B | — |
Source: Financial Modeling Prep · peers by sector/industry